Nilvadipine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Protected "Nilvadipine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{CMG}}, {{SS}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 459829456
| IUPAC_name = 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
| image = nilvapidine.png


'''Nilvadipine''' is prescribed for patients with both [[hypertension]] and chronic major cerebral artery [[occlusion]]. In hypertensive patients with high risk of [[atherosclerosis]], nilvadipine may protect [[LDL cholesterol]] from in vivo [[oxidation]]. Nilvadipine reduces [[infarction]] foci, improves cerebral microcirculation, but does not affect the systemic arterial blood pressure. Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine. Although it is a [[dihydropyridine]] derivative, nilvadipine has several kinetic, dynamic, and therapeutic effects that are different from even those of the other voltage-dependent Ca2+ channel blockers belonging to the same class. Nilvadipine could easily be transmitted to the [[central nervous system]]. Moreover, vascular smooth muscles contracted by [[potassium]] were reported to be inhibited by nilvadipine. It antagonizes both L- and T-type Ca2+ channels and exerts an antioxidant effect that is reported to be greater than the effects of [[nimodipine]], [[nicardipine]], and [[amlodipine]]. It has also been reported that nilvadipine (but not amlodipine) increased striatal [[dopamine]] and DOPAC contents and protected against motor deficits in mice.
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|nilvadipine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL        / P      / POM / CD -->
| legal_US = <!-- OTC                  / Rx-only  -->
| legal_status = 
| routes_of_administration = 


Currently Nilvadipine is tested in clinical trial as a possible treatment for [[Alzheimer's Disease]] in Ireland by the [[Roskamp Institute]], Florida, USA and Trinity College, Ireland. More information can be found [http://www.rfdn.org/news_release_090806_faq.html here].
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 


<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 
| ATC_prefix = C08
| ATC_suffix = CA10
| PubChem = 4494
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06712
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0214FUT37J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01908
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 517427
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 4338


{{pharma-stub}}
{{WikiDoc Sources}}


[[Category: Calcium channel blockers]][[Category: Selective calcium channel blockers with mainly vascular effects]][[Category: Dihydropyridine derivatives]][[Category: Cardiovascular Drugs]]
<!--Chemical data-->
[[Category: Drug]]
| C=19 | H=19 | N=3 | O=6
| molecular_weight = 385.370 g/mol
| smiles            = CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
| InChI            = 1/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
| InChIKey          = FAIIFDPAEUKBEP-UHFFFAOYAX
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey      = FAIIFDPAEUKBEP-UHFFFAOYSA-N
}}
__NOTOC__
{{SI}}
{{CMG}}
 
==Overview==
'''Nilvadipine''' is a [[calcium channel blocker]] (CCB) used for the treatment of [[hypertension]] and chronic major cerebral artery [[Vascular occlusion|occlusion]].
 
Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.
 
Nilvadipine was tested in clinical trial as a possible treatment for [[Alzheimer's Disease]] in Ireland by the [[Roskamp Institute]], Florida, USA and Trinity College, Ireland.<ref>[http://www.rfdn.org/news_release_090806_faq.html Roskamp Institute | ROSKAMP NILVADIPINE CLINICAL TRIAL Questions and Answers<!-- Bot generated title -->]</ref>
 
Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of Nilvadipine.<ref>[http://www.rfdn.org/news_release_052511.html Roskamp Institute | ROSKAMP NILVADIPINE CLINICAL TRIAL Press Release <!-- Bot generated title -->]</ref>
 
==References==
{{Reflist|2}}
 
{{Calcium channel blockers}}
 
[[Category:Calcium channel blockers]]
[[Category:Cardiovascular Drugs]]
[[Category:Drug]]

Latest revision as of 16:48, 20 August 2015

Nilvadipine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H19N3O6
Molar mass385.370 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Nilvadipine

Articles

Most recent articles on Nilvadipine

Most cited articles on Nilvadipine

Review articles on Nilvadipine

Articles on Nilvadipine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nilvadipine

Images of Nilvadipine

Photos of Nilvadipine

Podcasts & MP3s on Nilvadipine

Videos on Nilvadipine

Evidence Based Medicine

Cochrane Collaboration on Nilvadipine

Bandolier on Nilvadipine

TRIP on Nilvadipine

Clinical Trials

Ongoing Trials on Nilvadipine at Clinical Trials.gov

Trial results on Nilvadipine

Clinical Trials on Nilvadipine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nilvadipine

NICE Guidance on Nilvadipine

NHS PRODIGY Guidance

FDA on Nilvadipine

CDC on Nilvadipine

Books

Books on Nilvadipine

News

Nilvadipine in the news

Be alerted to news on Nilvadipine

News trends on Nilvadipine

Commentary

Blogs on Nilvadipine

Definitions

Definitions of Nilvadipine

Patient Resources / Community

Patient resources on Nilvadipine

Discussion groups on Nilvadipine

Patient Handouts on Nilvadipine

Directions to Hospitals Treating Nilvadipine

Risk calculators and risk factors for Nilvadipine

Healthcare Provider Resources

Symptoms of Nilvadipine

Causes & Risk Factors for Nilvadipine

Diagnostic studies for Nilvadipine

Treatment of Nilvadipine

Continuing Medical Education (CME)

CME Programs on Nilvadipine

International

Nilvadipine en Espanol

Nilvadipine en Francais

Business

Nilvadipine in the Marketplace

Patents on Nilvadipine

Experimental / Informatics

List of terms related to Nilvadipine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nilvadipine is a calcium channel blocker (CCB) used for the treatment of hypertension and chronic major cerebral artery occlusion.

Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.

Nilvadipine was tested in clinical trial as a possible treatment for Alzheimer's Disease in Ireland by the Roskamp Institute, Florida, USA and Trinity College, Ireland.[1]

Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of Nilvadipine.[2]

References

  1. ↑ Roskamp Institute | ROSKAMP NILVADIPINE CLINICAL TRIAL Questions and Answers
  2. ↑ Roskamp Institute | ROSKAMP NILVADIPINE CLINICAL TRIAL Press Release

Template:Calcium channel blockers

Retrieved from "https://www.wikidoc.org/index.php?title=Nilvadipine&oldid=1137134"